At this year’s meeting of the American Association for Clinical Chemistry, Instrumentation Laboratory, Bedford, Mass, featured its ACL Top Family 50 series of hemostasis testing systems, which received FDA premarket notification (510(k)) clearance in December 2015. Designed for mid- to high-volume clinical laboratories, including those using lab automation tracks, the systems aim to achieve a breakthrough in hemostasis quality management for routine and specialty testing.
The new family of systems was developed to offer preanalytical quality assurance, risk-management, and laboratory accreditation benefits. Automated preanalytical sample integrity checks identify underfilled sample tubes, abnormal sample aspiration potentially caused by clots, and assay-specific interference from hemolysis, icterus, and lipemia. Additionally, the new systems offer enhanced laboratory accreditation tools to automate documentation for compliance with quality standards.
The company’s systems “are designed to address the key challenges healthcare providers face today: improve patient care, improve patient satisfaction, and reduce total cost of care,” says Giovanni Russi, vice president of worldwide marketing at Instrumentation Laboratory. “Now, Instrumentation Laboratory can offer laboratories a complete and standardized hemostasis testing solution that automates preanalytical sample checks, and provides greater confidence in test results, lowers risk of clinical errors, and reduces unnecessary patient sample redraws.”
The series is a true standardized platform comprising five models: ACL Top 750 and ACL Top 750 CTS with closed-tube sampling for high-volume labs, ACL Top 750 LAS for lab automation tracks, ACL Top 550 CTS for mid- to high-volume labs, and ACL Top 350 CTS for mid-sized labs.
For more information, visit Instrumentation Laboratory.